Johnson & Johnson
Large public healthcare manufacturer and commercial products company.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Johnson & Johnson
- Entity type
- COMPANY
- Founded
- 1887
- Company size
- >5,000
- Market role
- Advertiser / Brand
- Ticker
- JNJ
- Official website
- jnj.com
What Johnson & Johnson does
The company creates value by developing, manufacturing, and distributing healthcare products at global scale. It monetises through product sales across professional healthcare and commercial channels, using its operating scale, brand equity, regulatory capabilities, and distribution relationships to generate recurring revenue.
Category differentiation
This is the public healthcare corporation, not an adtech, martech, or software platform. It should not be confused with any specific product brand, healthcare subsidiary, or unrelated Johnson-branded business.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Johnson & Johnson is a long-established public healthcare company. Based on the company name and widely established market identity, it operates as a large manufacturer and commercialiser of healthcare products, with revenue generated through the sale of medical, pharmaceutical, and consumer health-related products via healthcare channels and commercial distribution networks. The provided input confirms only that the company is active, founded in 1887, and operates at substantial scale with more than 5,000 employees and more than 1 billion in revenue. Because no product-level or customer-level extraction was supplied, customer and monetisation detail below is necessarily expressed at a high level.
Company news briefing
Briefing updated:
Following its Q2 2026 financial reporting, Johnson & Johnson has progressed its legal strategy via a conditional $5.5 billion talc settlement, aiming to resolve significant litigation. The group continues to serve as a primary defensive asset for investors during market rotations, bolstered by medtech advancements and ongoing operational modernisation. These developments reinforce J&J’s commitment to long-term stability, balancing portfolio management with the resolution of legacy liabilities within the healthcare sector.
Business model & monetisation
Primarily product-sales driven revenue from manufactured healthcare goods sold through commercial and healthcare distribution. The exact mix between pharmaceutical, medical technology, and consumer categories is not specified in the provided inputs, so pricing mechanisms cannot be broken down more precisely here.
Products & capabilities
No products with linked sources are available in this view.
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Recorded impact score: 4/5
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Recorded impact score: 3/5
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Recorded impact score: 4/5
Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation. First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA.
8-K Financial Filing Analysis for Johnson & Johnson (2026-08-04)
financials · Recorded impact score: 3.8/5
On August 4, 2026, Johnson & Johnson filed a Form 8-K announcing the retirement of Jennifer Taubert from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee, effective September 1, 2026. This represents a significant leadership transition for Johnson & Johnson's core pharmaceutical and innovative medicine division, which accounts for a substantial portion of the company's global revenue and R&D pipeline.
- Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine, effective September 1, 2026.
- Taubert will simultaneously step down from her role as a member of Johnson & Johnson's Executive Committee.
8-K Financial Filing Analysis for Johnson & Johnson
financials · Recorded impact score: 3.8/5
Johnson & Johnson filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on July 15, 2026, announcing its financial results for the fiscal second quarter ended June 28, 2026. The filing furnishes the official quarterly press release alongside unaudited comparative supplementary sales data and condensed consolidated statements of earnings for both the second quarter and the first six months of the fiscal year.
- Johnson & Johnson released its sales and earnings report for the second quarter ended June 28, 2026, via Item 2.02.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings).
Explore company relationships
Questions about Johnson & Johnson
What is Johnson & Johnson?
Johnson & Johnson is a large public healthcare company with a long operating history and substantial global scale.
Who uses Johnson & Johnson?
Its products are used by healthcare providers, institutions, distributors, retailers, pharmacies, and consumers, depending on the product category.
How does Johnson & Johnson make money?
It primarily makes money by selling healthcare products through professional and commercial distribution channels.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
8 publicly documented primary sources and citations linked across the market graph.
Continue your research on Johnson & Johnson
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.